Use of Antidepressants in Treatment of Comorbid Diabetes Mellitus and Depression as Well as in Diabetic Neuropathy

References

• Gavard JA, Lustman PJ, Clouse RE et at. Prevalence of de-pression in adults with diabetes: An epidemiologic evaluation. Diabetes Care 1993; 16:1167–1178
   PubMed Web of Science ®Google Scholar
• Karlson B, Argardh CD. Burden of illness, metabolic con-trol, and complications in relation to depressive symptoms in IDDM patients. Diabet Med 1997; 14(12):1066–1072
   Google Scholar
• Eaton WW, Armenian H, Gallo Jet al. Depression and risk for onset of type II diabetes. Diabetes Care 1996; 19:1097–1102
   PubMed Web of Science ®Google Scholar
• Kawakami N, Takatsuka N, Shimizu H et at. Depressive symp-toms and occurrence of type 2 diabetes among Japanese men. Diabetes Care 1999; 22(7):1071–1076
   Google Scholar
• Lustman PJ, Clouse RE, Carney RM. Depression and the reporting of diabetes symptoms. Int J Psychiatry Med 1988; 18:295–303
   Google Scholar
• Tun PA, Nathan DM, Perlmutter LC. Cognitive and affective disorders in elderly diabetics. Clin Geriatr Med 1990; 6:731–746
   Google Scholar
• Lustman PJ, Griffith LS, Clouse RE et at Psychiatric illness and diabetes mellitus. Relationship of symptoms to glucose control. J Nerv Ment Dis 1986; 174:736–742
   PubMed Web of Science ®Google Scholar
• Robinson N, Fuller JH, Edmeades SR Depression and dia-betes. Diabet Med 1987; 5:268–274
   Google Scholar
• Cohen ST, Welch G, Jacobson AM et at. The association of lifetime pschiatric illness and increased retinopathy in patients with type I diabetes mellitus. Psychosomatics 1997; 38:98–108
   Google Scholar
• de Groot M, Jacobson AM, Samson JA et at. Glycemic control and major depression in patients with type 1 and type 2 diabetes mellitus. J Psychosomatic Res 1999; 46(5): 425–435
   Google Scholar
• Okamura F, Tashiro A, Utsumi A et at. Insulin resistance in patients with depression and its changes in the clinical course of depression: A report on three cases using the minimal model analysis. Internal Med 1999; 38(3):257–260
   Google Scholar
• Marangou AG, Alford FP, Ward G et at. Hormonal effects of norepinephrine on acute glucose disposal in humans: A mini-mal model analysis. Metabolism 1988; 37(9):885–891
   Google Scholar
• Lundquist I, Ekholm R, Ericson LE. Monoamine in the pan-creatic islets of the mouse. Diabetologia 1971; 7:414–422
   Google Scholar
• Furman BL. The hypoglycemic effect of 5-hydroxytrytophan. Br J Pharmacol 1974; 50:575–580
   Google Scholar
• Wilson GA, Furman BL. Effects of inhibitors to 5-hydroxytryptamine uptake on plasma glucose and their inter-actions with 5-hydroxytryptophan in producing hypoglycemia in mice. Eur J Pharmacol 1982; 78:263–270
   PubMed Web of Science ®Google Scholar
• Furman BL, Wilson GL. Further studies on the effects of 5-hydroxytryptophan on plasma glucose and insulin in the mouse. Diabetologia 1980; 19:386–390
   PubMed Web of Science ®Google Scholar
• Peschke E, Peschke D, Hammer T et at. Influence of melatonin and serotonin on glucose-stimulated insulin release from per-ifused rat pancreatic islets in vitro. J Pineal Res 1997; 23(3): 156–163
   Google Scholar
• Schaeffer HJ, Sirotkin AV. Melatonin and serotonin regulate the release of insulin-like growth factor-I, oxytocin, and pro-gesterone by cultured granolosa cells. Exp Clin Endocrinol Diabetes 1997; 105(2):109–112
   Google Scholar
• Hajduch E, Rencurel F, Balendran A et al. Serotonin: a novel regulator of glucose transport in rat skeletal muscle. J Biol Chem 1999; 274(19):13563–13568
   Google Scholar
• Pestell RG, Crock PA, Ward GM. Fenfluramine increases in-sulin action in patients with NIDDM. Diabetes Care 1989; 12:252–258
   Google Scholar
• Sheen AJ, Paloisso G, Salvatore T. Improvement of insulin-induced glucose disposal in obese patients with NIDDM after 1 week treatment with d-fenfluramine. Diabetes Care 1991; 14:325–332
   Google Scholar
• Greco AV, Mingrone G, Capristo E et at Effects of dexfen-fluramine on free fatty acid turnover and oxidation in obese patients with type 2 diabetes mellitus. Metabolism 1995; 442(Suppl 2):57–61
   Google Scholar
• Willey KA, Molyneaux LM, Yue DK. Obese patients with type 2 diabetes poorly controlled by insulin and metformin: Effects of adjunctive dexfenfluramine therapy on glycemic control. Diabet Med 1994; 11:701–704
   Google Scholar
• Richelson E. Pharmacology of antidepressants-characteris-tics of the ideal drug. Mayo Clin Proc 1994; 69:1069–1081
   PubMed Web of Science ®Google Scholar
• Kaplan SM, Maas IW, Pixley JM et at. Use of imipramine in diabetics. JAMA 1960; 174:511–517
   Google Scholar
• El-Dakhakny M, Abdel el-Latif HA, Ammon HP. Differnt ef-fects of the antidepressant drugs irnipramine, maprotiline, and bupropion on insulin secretion from mouse pancreatic islets. Arzneimittelforshung 1996; 46(7):667–669
   Google Scholar
• Erenmemisolglu A, Ozdogan UK, Saraymen R et al. Effect of some antidepressants on glycaemia and insulin levels of normoglycaemic and alloxan-induced hyperglycaemic mice. J Pharm Pharmacol 1999; 51(6):741–743
   Google Scholar
• Lustman PJ, Griffith LS, Clouse RE et at. Effects of nortripty-line on depression and glycemic control in diabetes: Results of a double-blind, placebo-controlled trial. Psychosom Med 1997; 59(3):241–250
   Google Scholar
• Isotani H, Kameoka K. Hypoglycemia associated with mapro-tiline in a patient with type I diabetes. Diabetes Care 1999; 22(5):862,863
   Google Scholar
• Rowland DL, Myers L, Culver A et al. Bupropion and sexual function: A placebo-controlled prospective study on diabetic men with erectile dysfunction. J Clin Psychopharmacol 1997; 17(5):350–357
   Google Scholar
• Hakanson R, Lundquist 1, Rerup C. On the hyperglycemic effect of dopa and dopamine. Fur J Pharmacol 1967; 1:114–119
   Google Scholar
• Aleyassine H, Lee SH. Inhibition of insulin release by sub-strates and inhibitors of monoamine oxidase. Am J Physiol 1972; 222:565–569
   Google Scholar
• Feldman JM. Inhibition of pancreatic islet monoamine oxidase by adrenergic antagonists and ethanol. Endocrine Res Comm 1976; 2:503–520
   Google Scholar
• Lekas MC, Fisher Si, El-Bahrani B et aL Glucose uptake during centrally induced stress is insulin independent and enhanced by adrenergic blockade. J Appl Physiol 1999; 87(2):722–731
   Google Scholar
• Walters JM, Ward GM, Barton J et aL The effect of norepinephrine on insulin secretion and glucose effective-ness in non-insulin-dependent diabetes. Metabolism 1997; 46(12):1448–1453
   PubMed Web of Science ®Google Scholar
• Silver K, Mitchell BD, Walston J et aL TRP64ARG beta 3-adrenergic receptor and obesity in Mexican Americans. Hum Genet 1997; 101(3):306–311
   Google Scholar
• Max MB, Kishore-Kumar R, Schafer SC etal. Efficacy of desi-pramine in painful diabetic neuropathy: A placebo-controlled trial. Pain 1991; 45:3–9
   Google Scholar
• Warnock JK. Nefazodone-induced hypoglycemia. Am J Psy-chiatry 1997; 154:288–289
   PubMed Web of Science ®Google Scholar
• Dejgaard A. Pathophysiology and treatment of diabetic neu-ropathy. Diabet Med 1998; 15:97–112
   Google Scholar
• Potter Van Loon BJ, Radder JK, Frolich M et al. Fluoxetine increases insulin action in obese nondiabetic and in obese non-insulin-dependent diabetic individuals. Int J Obesity 1992; 16(2):79–85
   Google Scholar
• Gray DS, Fujioka K, Devine W et al. Fluoxetine treatment of the obese diabetic. Int .1- Obesity 1992; 16:193–198
   Web of Science ®Google Scholar
• O'Kane M, Wiles PG, Wales JK. Fluoxetine in the treatment of obese type 2 diabetic patients. Diabet Med 1994; 11:105–110
   PubMed Web of Science ®Google Scholar
• Connolly VM, Gallagher A, Kesson CM. A study of flu oxetine in obese elderly patients with type 2 diabetes. Diabet Med 1995; 12(5):416–418
   Google Scholar
• Maheux P, Ducros F, Bourque J et aL Fluoxetine improves in-sulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss. Int J Obesity 1997; 21(2):97–102
   Web of Science ®Google Scholar
• Goodnick RI, Kumar AH, Henry .TH, Buki V, Goldberg R. Sertraline in coexisting major depression and diabetes melli-tus. Psychopharmacol Bull 1997; 33(2):261–264
   Google Scholar
• Lustman RI, Freedland KE, Griffith LS, Clouse RE. Fluoxetine for depression in diabetes. Diabetes Care 2000; 23(5):618–623
   PubMed Web of Science ®Google Scholar
• Bressler R, Johnson D. New pharmacological approaches to therapy of NIDDM. Diabetes Care 1992; 15:792–805
   Web of Science ®Google Scholar
• Cooper AT, Keddie ICMG. Hypotensive collapse and hypo-glycemia after mebanazine, a monoamine oxidase inhibitor. Lancet 1964; 1:1133–1135
   Google Scholar
• Van Praag HM, Leijnst B. Depression, glucose tolerance, pe-ripheral glucose uptake, and their alterations under the in-fluence of antidepressive drugs of the hydrazine type. Psy-chopharamacology (Berl) 1965; 8:67–78
   Google Scholar
• Cooper AT, Ashcroft G. Potentiation of insulin hypoglycemia by MAOI antidepressant drugs. Lancet 1966; 11407–409
   Google Scholar
• Rabkin J, Quitkin F, Harrison W, et al. Adverse reactions to monoamine oxidase inhibitors: I: A comparative study. J Clin Psychopharmacol 1984; 4:270–278
   PubMed Web of Science ®Google Scholar
• Cole JO, Bodkin JA. Antidepressant drug side effects. J Clin Psychiatry 1990; 51(1, Suppl 2):21–26
   Google Scholar
• Rosenstock J, Cercone S, Koffier Metal. The effects of the sero-tonin reuptake inhibitor, fluoxetine, on weight loss, glycemic control, and lipid levels in non-insulin dependent diabetes mel-litus. Diabetes 1987; 36(Suppl 1:46A)
   Google Scholar
• Reimherr FW, Chouinard G, Cohn CK et aL Antidepres-sant efficacy of sertraline: A double-blind, placebo- and amitriptyline-controlled multicenter comparison study in out-patients with major depression. J Clin Psychiatry 1990; 51(12, Suppl B): 18–27
   Google Scholar
• Levitt AT, Joffe RT, Esche I. The effect of desipramine on body weight in depression. J Clin Psychiatry 1987; 48:27,28
   Google Scholar
• Paykel ES, Mueller PS, De La Vergne PM. Amitriptyline, weight gain, and carbohydrate cravings: A side effect. Br J Psychiatry 1973; 123:501–507
   Google Scholar
• Nakra BRS, Rutland P, Verma Set aL Amitriptyline and weight gain: A biochemical and endocrinological study. Curr Med Res Opin 1977; 4:602–606
   PubMed Web of Science ®Google Scholar
• Harris B, Young J, Hughes B. Changes occurring in appetite and weight during short-term antidepressant treatment. Br J Psychiatry 1984; 145:645–648
   Google Scholar
• Berken GH, Weinstein DO, Stem WC. Weight gain: A side effect of tricyclic antidepressants. J Affect Dis 1984; 7:133 [let]
   Google Scholar
• Fernstrom MH, Krowinsld RL, Kupfer DJ. Appetite an food preference in depression: Effects of imipramine treatment. Biol Psychiatry 1987; 22:529–539
   Google Scholar
• Stein EM, Stein S, Linn MW. Geriatric sweet tooth. J Am Geriatr Soc 1985; 33:687–692
   Google Scholar
• Workman EA, Short DD. Bupropion-induced carbohydrate cravings. Am J Psychiatry 1992; 149:1407,1408
   Google Scholar
• Mitchell GF, Mebane AR, Billings CK. Effect of bupropion on chocolate cravings. Am .1 Psychiatry 1989; 146: 119,120
   Google Scholar
• Physicians' Desk Reference, 53rd Ed, Montvale, NJ: Medical Economics Co; 1999
   Google Scholar
• Sussman N, Ginsberg D. Weight gain associated with SSRIs. Primary Psychiatry 1998; 5(1):28–37
   Google Scholar
• Vinik Al. Diagnosis and management of diabetic neuropathy. Clin Geriatr Med 1999; 15(2):293–320
   Google Scholar
• Pirart J. Diabetes mellitus and its degenerative complications: A prospective study of 4400 patients observed. Diabetes Care 1978; 1:168–178
   Google Scholar
• Gomez-Perez ET, Rull JA, Dies H et al. Nortriptyline and fluphenazine in the symptomatic treatment of diabetic neu-ropathy: A double blind cross over study. Pain 1985; 23:395–400
   PubMed Web of Science ®Google Scholar
• Kvinesdal B, Molin D, Froland A, etal. Imiprarnine therapy of painful diabetic neuropathy. JAMA 1984; 251:1727–1730
   PubMed Web of Science ®Google Scholar
• Sindrup SH, Ejlertsen B, Froland A et aL Imipramine treat-ment in diabetic neuropathy: Relief of subjective symptoms without changes in peripheral and autonomic nerve function. Eur J Clin Pharmacol 1989; 37:151–153
   PubMed Web of Science ®Google Scholar
• Max MB, Culnane M, Schafer SC et aL Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1987; 37:589–596
   PubMed Web of Science ®Google Scholar
• Sindrup SH, Gram LF, Skjold T et al. Clomipramine vs. de-sipramine vs placebo in the treatment of diabetic neuropathy symptoms: A double-blind cross-over study. Br J Clin Phar-macol 1990; 30:683–691
   Google Scholar
• Max MB, Lynch SA, Muir J et aL Effects of desipramine, amitriptyline, and fluoxetine in diabetic neuropathy. N Engl J Med 1992; 326:1250–1256
   PubMed Web of Science ®Google Scholar
• Sindrup SH, Grodum E, Gram LF et al. Concentration-response relationship in paroxetine treatment of diabetic neu-ropathy symptoms: A patient-blinded dose-escalation study. 'Ther Drug Monit 1990; 13:408–414
   Google Scholar
• Sindrup SH, Gram LF, Brosen K et al. The selective sero-tonin reuptake inhibitor paroxetine is effective in the treat-ment of diabetic neuropathy symptoms. Pain 1990; 42:135–144
   PubMed Web of Science ®Google Scholar
• Sindrup SH, Bjerre U, Dejaard A et al. The selective sero-tonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther 1992; 52:547–552
   PubMed Web of Science ®Google Scholar
• Goodnick PJ, Jimenez I, Kumar A. Sertraline in diabetic neu-ropathy. Ann Clin Psychiatry 1997; 9:255–257
   Google Scholar
• Goodnick 131, Mendosa L, Kumar A et aL Sertraline in dia-betic neuropathy: response and biology. Psychosom Med 2000; 62:461–462
   Google Scholar
• Sindrup SH, Tuxen C, Gram LF et aL Lack of effect of mi-anserin on the symptoms of diabetic neuropathy. Eur J Clin Pharmacol 1992; 43:251–255
   PubMed Web of Science ®Google Scholar
• Semenchuk MR, Davis B. Efficacy of bupropion SR in neuro-pathic pain: An open-label study. (Kuhn T, personal commu-nication, 1999)
   Google Scholar
• Kunz NR, Goli V, Entsuah R et al. Diabetic neuropathic pain management with venlafaxine extended release. Presented at ADA Annual Meeting, June 2000 (Cantillon M, personal com-munication, 2000)
   Google Scholar
• Goodnick PJ, Breakstone K, Kumar A et al. Nefazodone in diabetic neuropathy: Response and biology. Psychosom Med 2000; 62:599, 600
   Google Scholar
• Nonogaki K, Strack AM, Dallman MF et al. Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated 5-HT2c receptor gene. Nat Med 1998; 4(10)1152–1156
   Google Scholar